

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **August, 2018**

Commission File Number: **001-38480**

**IMV Inc.**

*(Name of registrant)*

**130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IMV Inc.**

Date: August 23, 2018

By: /s/ Pierre Labbé

Name: Pierre Labbé

Title: Chief Financial Officer

---

Form 6-K Exhibit Index

**Exhibit  
Number**

**Document Description**

[99.1](#)

[News Release dated August 23, 2018 announcing company's presentation at the H.C. Wainwright 20th Annual Global Investment Conference on September 6th 2018.](#)

---



**FOR IMMEDIATE RELEASE**

**IMV Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference**

**Halifax, Nova Scotia; August 23, 2018** – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors and Chief Financial Officer Pierre Labbé will present a corporate update at the H.C. Wainwright 20th Annual Global Investment Conference, which takes place September 5 – 6, 2018, in New York, NY.

IMV's presentation details include:

- **Date:** Thursday, September 6, 2018
- **Time:** 12:05 – 12:30 p.m. ET
- **Location:** The Library (Second Floor), The St. Regis Hotel

There will be a live webcast of IMV's presentation accessible via the following URL: <http://wsw.com/webcast/rrshq28/imv/>. The webcast will be archived for 90 days following the live presentation. A copy of the presentation will be available on the Events & Presentations page of IMV's website: [www.imv-inc.com](http://www.imv-inc.com).

**About IMV**

IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company's proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells *in vivo*, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV's lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at [www.imv-inc.com](http://www.imv-inc.com).

###

**Contacts for IMV:**

**MEDIA**

**Mike Beyer, Sam Brown Inc.**

T: (312) 961-2502 E: [mikebeyer@sambrown.com](mailto:mikebeyer@sambrown.com)

**INVESTOR RELATIONS**

---

**Pierre Labbé, Chief Financial Officer**

T: (902) 492-1819 E: [info@imv-inc.com](mailto:info@imv-inc.com)

**Patti Bank, Managing Director, Westwicke Partners**

O: (415) 513-1284

T: (415) 515-4572 E: [patti.bank@westwicke.com](mailto:patti.bank@westwicke.com)

---